Literature DB >> 26550131

Glucocorticoids offer protection against myocardial injury in a murine model of sepsis.

Zhong-Qian Lu1, Jian-Xia Lu2, Yi-Jun Deng1.   

Abstract

Sepsis is a serious infection-related complication that, in causing significant inflammation, often leads to myocardial injury. Severe inflammation, including in sepsis, is sometimes treated with exogenous glucocorticoids (GCs). Here, to explore the potential effect of GCs to protect against myocardial injury, we created a model of sepsis in rats by performing cecal ligation and puncture (CLP) in 96 rats randomly divided into sham-operated control (N=32), untreated sepsis (CLP, N=32), and GC-treated sepsis (N=32) groups. At 3, 6, 12, and 24 h after surgery, the changes in cardiac hemodynamic indexes, serum inflammatory response factor levels, and myocardial enzymes were measured, along with mitochondrial membrane potential in myocardial cells, apoptosis of myocardial cells, and the expression of nuclear factor kappa B (NF-κB p65) in myocardial tissues. Pathological changes in myocardial cells were also observed. Compared to the sham-operated group, CLP rats experienced deterioration of left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), maximum rate of left ventricular pressure rise (+dP/dtmax), and the maximum rate of left ventricular pressure drop (-dP/dtmax). CLP rats also had a rise in serum tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP), cardiac troponin I (cTnI), creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and NF-κB p65 in myocardial tissues. The GCs-treated group had lower levels of these inflammatory response molecules than the CLP group, with the exception of anti-inflammatory cytokine interleukin-10 (IL-10), which was higher in the GC-treated rats than the CLP group at each time point post-surgery. Compared to the sham group, CLP rats had a rise in myocardial cell apoptosis and a drop in mitochondrial membrane potential in myocardial cells. In addition, GCs-treated rats had a marked drop in the myocardial cell apoptosis rate and a rise in the mitochondrial membrane potential compared to CLP rats. After intervention with GCs, the pathological changes in heart tissues were also reduced compared to those in the sepsis group. Based on these results, we conclude that exogenous GCs can inhibit a drop in myocardial mitochondrial membrane potential and inhibit myocardial cell apoptosis by blocking the activation of NF-κB, decreasing the generation of proinflammatory cytokines, and relieving inflammatory injury in heart tissues.

Entities:  

Keywords:  Myocardial injury; apoptosis; mitochondrial membrane potential; nuclear transcription factor; rat

Year:  2015        PMID: 26550131      PMCID: PMC4612816     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

1.  A dog model for acetaminophen-induced fulminant hepatic failure.

Authors:  A Francavilla; L Makowka; L Polimeno; M Barone; J Demetris; J Prelich; D H Van Thiel; T E Starzl
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

2.  An improved model of galactosamine-induced fulminant hepatic failure in the pig.

Authors:  K Kalpana; H S Ong; K C Soo; S Y Tan; J Prema Raj
Journal:  J Surg Res       Date:  1999-04       Impact factor: 2.192

3.  Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.

Authors:  Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione
Journal:  Am J Gastroenterol       Date:  2011-11-22       Impact factor: 10.864

Review 4.  Review article: the role of non-biological drugs in refractory inflammatory bowel disease.

Authors:  S C Ng; F K L Chan; J J Y Sung
Journal:  Aliment Pharmacol Ther       Date:  2010-12-08       Impact factor: 8.171

5.  Intrahepatic amino acid and glucose metabolism in a D-galactosamine-induced rat liver failure model.

Authors:  K Arai; K Lee; F Berthiaume; R G Tompkins; M L Yarmush
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

Review 6.  Etiologies of acute liver failure.

Authors:  William M Lee
Journal:  Semin Liver Dis       Date:  2008-05       Impact factor: 6.115

Review 7.  An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure.

Authors:  María-Jesús Tuñón; Marcelino Alvarez; Jesús-M Culebras; Javier González-Gallego
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

8.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.

Authors:  H Ogata; T Matsui; M Nakamura; M Iida; M Takazoe; Y Suzuki; T Hibi
Journal:  Gut       Date:  2006-02-16       Impact factor: 23.059

9.  Acute hepatic failure in swine: hepatectomy versus vascular occlusion.

Authors:  Nils R Frühauf; Karl J Oldhafer; Stephanie Westermann; Georgios C Sotiropoulos; Gernot M Kaiser
Journal:  J Invest Surg       Date:  2004 May-Jun       Impact factor: 2.533

10.  Differential oxidase activity of hepatic and pulmonary microsomal cytochrome P-450 isozymes after treatment with cytochrome P-450 inducers.

Authors:  H Sakai; S S Park; Y Kikkawa
Journal:  Biochem Biophys Res Commun       Date:  1992-09-30       Impact factor: 3.575

View more
  3 in total

1.  Resolvin D1 Promotes SIRT1 Expression to Counteract the Activation of STAT3 and NF-κB in Mice with Septic-Associated Lung Injury.

Authors:  Yuzhen Zhuo; Shukun Zhang; Caixia Li; Lei Yang; Hongwei Gao; Ximo Wang
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

2.  Exploring the beneficial role of telmisartan in sepsis-induced myocardial injury through inhibition of high-mobility group box 1 and glycogen synthase kinase-3β/nuclear factor-κB pathway.

Authors:  Yan Jin; Hong Wang; Jing Li; Minyan Dang; Wenzhi Zhang; Yan Lei; Hao Zhao
Journal:  Korean J Physiol Pharmacol       Date:  2020-07-01       Impact factor: 2.016

3.  MicroRNA-181b Inhibits Inflammatory Response and Reduces Myocardial Injury in Sepsis by Downregulating HMGB1.

Authors:  Lan Ling; Haifeng Wang; Lida Zhi; Yihuan Deng; Chengdong Gu
Journal:  Inflammation       Date:  2021-06-02       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.